Siglec-15 as a New Perspective Therapy Target in Human Giant Cell Tumor of Bone.

The main features of a giant cell tumor of bone (GCTB) are frequent recurrence and aggressive osteolysis, which leads to a poor prognosis in patients. Although the treatment methods for a GCTB, such as scraping and resection, effectively inhibit the disease, the tendency toward malignant transformat...

Descripción completa

Detalles Bibliográficos
Publicado en:Current Oncology Vol. 29; no. 10; pp. 7655 - 7672
Autores principales: Fan, Mengke, Zhang, Guochuan, Xie, Mingfang, Liu, Xinbo, Zhang, Qi, Wang, Ling
Formato: Journal Article
Publicado: MDPI Oct2022
Acceso en línea:Ver este registro en EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=159900863&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 159900863
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        11980052
        5EKK
      jtl: Current Oncology
      issn: 11980052
      maglogo: N
    pubinfo:
      dt: Oct2022
      vid: 29
      iid: 10
      pid: 97109
      pub: MDPI
    artinfo:
      ui:
        159900863
        10.3390/curroncol29100605
        159900863
      ppf: 7655
      ppct: 17
      formats:
        fmt:
          – @attributes:
              type: T
          – @attributes:
              type: P
      tig:
        atl: Siglec-15 as a New Perspective Therapy Target in Human Giant Cell Tumor of Bone.
      aug:
        au:
          Fan, Mengke
          Zhang, Guochuan
          Xie, Mingfang
          Liu, Xinbo
          Zhang, Qi
          Wang, Ling
        affil: Department of Orthopedic Research Center, Third Hospital of Hebei Medical University, Shijiazhuang 050051, China
      sug:
      ab: The main features of a giant cell tumor of bone (GCTB) are frequent recurrence and aggressive osteolysis, which leads to a poor prognosis in patients. Although the treatment methods for a GCTB, such as scraping and resection, effectively inhibit the disease, the tendency toward malignant transformation remains. Therefore, it is important to identify new treatment methods for a GCTB. In this study, we first found high Siglec-15 expression in GCTB tissues, which was significantly associated with Campanacci staging and tumor recurrence. In Spearman's analysis, Siglec-15 expression was significantly correlated with Ki-67 levels in tumor tissues. In vitro, the mRNA and protein levels of Siglec-15 were high in GCTB stromal cells (Hs737. T), and Siglec-15 knockdown inhibited the biological characteristics of GCTB stromal cells. The RNA sequencing results enabled a prediction of the downstream genes by using the Kyoto Encyclopedia of Genes and Genomes (KEGG), Gene Ontology (GO), and MCODE analyses, and the findings showed that CXCL8 was significantly regulated by Siglec-15 and might be a promising downstream target gene of Siglec-15. Therefore, Siglec-15 may be a potential immunotherapy target for a GCTB.
      pubtype: Academic Journal
      doctype: Journal Article
      ougenre: Article
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N